Stock Taper
BMEA
BIOMEA FUSION, INC.
NASDAQ
$1.73
▲ UP 2.98% (0.05)

KEY STATISTICS

Market Cap$125.08 M
52w High$2.99
52w Low$0.87
Dividend Yield
Frequency
P/E-1.44
Volume1.16M
Shares Out.72.30M

COMPANY

LEADERSHIP

Michael J. Hitchcock
CHIEF EXECUTIVE
Michael J. Hitchcock

COMPENSATION 2026

Salary$148,801
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$513,162
Total$661,963

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 16, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
37

PRICE TARGET

Target High$40.00
Target Low$10.00
Target Median$19.00
Target Consensus$20.20

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.
NOV
3
TUE

PRICE

$1.73 ▲ UP 2.98% (+$0.05)
$1.68$1.70$1.729:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.73

About Biomea Fusion, Inc.

https://biomeafusion.com ↗

Biomea Fusion, Inc. is a biopharmaceutical company founded in 2017 in Redwood City, CA, developing covalent small molecule drugs like BMF-219 to treat genetically defined cancers and metabolic diseases.

INDUSTRY

Biotechnology

A SERVICE BIOMEA FUSION, INC. IS KNOWN FOR

Development of Icovamenib and BMF-650

Biomea Fusion is a clinical-stage company developing oral medications for diabetes and obesity, including Icovamenib to regenerate insulin cells and BMF-650, a GLP-1 receptor agonist.

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

DIRECTOR
Averill Julianne
Purchase · 173.7K shares
2026-06-10
DIRECTOR
AGUIAR ERIC
Purchase · 196.3K shares
2026-06-10
DIRECTOR
Ray Sumita
Purchase · 196.3K shares
2026-06-10
DIRECTOR
Faust Elizabeth
Purchase · 196.3K shares
2026-06-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
ALXO$2.00COMPARE
IMUX$15.40COMPARE
STRO$20.45COMPARE
UNCY$5.26COMPARE
CBUS$1.65COMPARE
GUTS$0.66COMPARE
CAMP$4.15COMPARE
PMVP$1.22COMPARE